Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Paniccia

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|December 27, 2023
Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic CancerPranav Murthy, Mazen S Zenati, Samer S AlMasri, et al.
Cancers|May 13, 2026
A Biomarker Panel for the Detection of Pancreatic CancerYuefan Wang, Yuanyu Huang, Tung-Shing M Lih, et al.
JAMA Surgery|November 23, 2022
Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant TherapyAbdulrahman Y Hammad, Jacob C Hodges, Samer AlMasri, et al.
Annals of Surgery|August 24, 2022
Robotic Pancreaticoduodenectomy: Increased Adoption and Improved Outcomes: Is Laparoscopy Still Justified?Hussein H Khachfe, Ibrahim Nassour, Abdulrahman Y Hammad, et al.
JAMA Network Open|June 23, 2022
Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic CancerSamer AlMasri, Mazen Zenati, Abdulrahman Hammad, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 16, 2020
Long-Term Surgical Complications After Pancreatoduodenectomy: Incidence, Outcomes, and Risk FactorsJames A Brown, Mazen S Zenati, Richard L Simmons, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|February 22, 2023
No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancerHao Liu, Mark D'Alesio, Samer AlMasri, et al.
Annals of Surgical Oncology|March 31, 2020
Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head AdenocarcinomaAlessandro Paniccia, Ana L Gleisner, Mazen S Zenati, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 3, 2021
Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic AdenocarcinomaAsmita Chopra, Ruben Zamora, Yoram Vodovotz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 12, 2025
Lessons Learned About Acute and Late Toxicity After Two Decades of Experience With Pancreatic SBRTSusannah G Ellsworth, Mohamed Abdelhakiem, Baher Elgohari, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Journal of the National Comprehensive Cancer Network : JNCCN|December 27, 2023
Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic CancerPranav Murthy, Mazen S Zenati, Samer S AlMasri, et al.
Cancers|May 13, 2026
A Biomarker Panel for the Detection of Pancreatic CancerYuefan Wang, Yuanyu Huang, Tung-Shing M Lih, et al.
JAMA Surgery|November 23, 2022
Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant TherapyAbdulrahman Y Hammad, Jacob C Hodges, Samer AlMasri, et al.
Annals of Surgery|August 24, 2022
Robotic Pancreaticoduodenectomy: Increased Adoption and Improved Outcomes: Is Laparoscopy Still Justified?Hussein H Khachfe, Ibrahim Nassour, Abdulrahman Y Hammad, et al.
JAMA Network Open|June 23, 2022
Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic CancerSamer AlMasri, Mazen Zenati, Abdulrahman Hammad, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 16, 2020
Long-Term Surgical Complications After Pancreatoduodenectomy: Incidence, Outcomes, and Risk FactorsJames A Brown, Mazen S Zenati, Richard L Simmons, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|February 22, 2023
No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancerHao Liu, Mark D'Alesio, Samer AlMasri, et al.
Annals of Surgical Oncology|March 31, 2020
Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head AdenocarcinomaAlessandro Paniccia, Ana L Gleisner, Mazen S Zenati, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 3, 2021
Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic AdenocarcinomaAsmita Chopra, Ruben Zamora, Yoram Vodovotz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 12, 2025
Lessons Learned About Acute and Late Toxicity After Two Decades of Experience With Pancreatic SBRTSusannah G Ellsworth, Mohamed Abdelhakiem, Baher Elgohari, et al.
Pageof 12